Rocket Pharmaceuticals, Inc. (RCKT) stock
RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11−0.05 (-2.31%)
Close on Nov 17, 2026Market cap $231.62MP/E –Yield –
Rocket Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rocket Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$184.04M. For fiscal 2025 it was -$222.85M. The highest annual figure on record is -$70.83M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$222.85M | – |
| FY2024 | Dec 31, 2024 | -$266.01M | – |
| FY2023 | Dec 31, 2023 | -$254.76M | – |
| FY2022 | Dec 31, 2022 | -$220.44M | – |
| FY2021 | Dec 31, 2021 | -$164.05M | – |
| FY2020 | Dec 31, 2020 | -$133.16M | – |
| FY2019 | Dec 31, 2019 | -$75.73M | – |
| FY2018 | Dec 31, 2018 | -$70.83M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$45.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$49.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$69.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$61.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$60.89M | – |
| Q3 FY2024 | Sep 30, 2024 | -$67.52M | – |
| Q2 FY2024 | Jun 30, 2024 | -$71.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$65.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$61.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$64.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$67.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$61.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$43.32M | – |
| Q3 FY2021 | Sep 30, 2021 | -$48.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$33.35M | – |
| Q1 FY2021 | Mar 31, 2021 | -$38.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$58.61M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.09M | – |
| Q2 FY2020 | Jun 30, 2020 | -$23.46M | – |
| Q1 FY2020 | Mar 31, 2020 | -$24.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.55M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.07M | – |
See a number that looks wrong?